You are here

SARC Clinical Trials

Every day, our community of researchers, investigators, scientists, sarcoma centers, and biotech and pharmaceutical companies are working together in the development and support of clinical trials (studies). A list of SARC trials is provided here with a brief description and patient accrual status. Additionally, the National Institutes of Health provides an online registry and results database of clinical studies conducted around the world at ClinicalTrials.gov.

Patient participating in sarcoma trial

Active SARC Trials

SU2C - SARC032 - SPORE05
SU2C-SARC032: A Phase II Randomized Controlled Trial of Neoadjuvant Pembrolizumab With Radiotherapy and Adjuvant Pembrolizumab
Type of Sarcoma: Soft Tissue Sarcoma of the Extremity
Drug: Pembrolizumab
Accrual Status: Recruiting
Overall Study Principal Investigator:
David Kirsch, MD, PhD
Professor, Radiation Oncology / Professor of Pharmacology and Cell Biology
Duke University
SARC033 - SPORE06
Trametinib in Treating Patients With Epithelioid Hemangioendothelioma That Is Metastatic, Locally Advanced, or Cannot Be Removed by Surgery
Type of Sarcoma: Epithelioid Hemangioendothelioma
Drug: Trametnib
Accrual Status: Recruiting
Overall Study Principal Investigator:
Scott Schuetze, MD, PhD
Division of Hematology/Oncology
University of Michigan
 
SARC028
A phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients with Advanced Sarcomas
Type of Sarcoma: Undifferentiated Pleomorphic Sarcoma and Poorly Differentiated/Dedifferentiated Liposarcoma
Drug: Pembrolizumab
Accrual Status: Recruiting
Overall Study Principal Investigator:
Hussein Tawbi, MD
Associate Professor of Medicine
MD Anderson Cancer Center
SARC024
SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Refractory Liposarcoma, Osteogenic Sarcoma, and Ewing Sarcomas
Type of Sarcoma: Refractory liposarcoma, osteogenic sarcoma, Ewing/Ewing-like sarcomas
Drug: Regorafenib and placebo (for liposarcoma and osteogenic sarcoma only)
Accrual Status: Recruiting
Overall Study Principal Investigator:
Robert Maki, MD, PhD
Professor Pediatrics, Hematology & Oncology
Hofstra-Northwell School of Medicine

Richard F. Riedel, MD
Associate Professor of Medicine
Duke University School of Medicine

Christopher W. Ryan, MD
Medical Oncologist
Oregon Health and Science University

Steven Attia, DO
Medical Oncologist
Mayo Clinic
SARC023
SARC023: Ganetespib and Sirolimos in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors)
Type of Sarcoma: Phase I all unresectable soft tissue or bone sarcomas and Phase II unresectable malignant peripheral nerve sheath tumor (MPNST)
Drug: ganetespib and sirolimus
Accrual Status: Ongoing,Not Accruing
Overall Study Principal Investigator:

AeRang Kim, MD, PhD
Pediatric Oncologist
Children’s National Medical Center

SARC018 - SPORE01
SARC018: A Study of Mocetinostat and Gemcitabine in Patients With Metastatic Leiomyosarcoma
Type of Sarcoma: Metastatic Leiomyosarcoma
Drug: Mocetinostat & Gemcitabine
Accrual Status: Ongoing,Not Accruing
Overall Study Principal Investigator:
Shreyas Patel, MD
Co-Principal Investigator
MD Anderson Cancer Center

Edwin Choy, MD, PhD
Co-Principal Investigator
MGH, Dana Farber/Harvard Cancer Center
Division of Hematology Oncology
 
SARC016
SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors
Type of Sarcoma: Malignant Peripheral Nerve Sheath Tumor (MPNST) either Sporadic or NF1 Associated
Drug: Bevacizumab and Everolimus
Accrual Status: Ongoing,Not Accruing
Overall Study Principal Investigator:

Brigitte Widemann, MD
Senior Investigator, Pediatric Oncology Branch
National Cancer Institute

SARC012
A Placebo-Controlled Study of Saracatinib (AZD0530) in Patients With Recurrent Osteosarcoma Localized to the Lung
Type of Sarcoma: Osteosarcoma
Drug: saracatinib and placebo
Accrual Status: Ongoing,Not Accruing
Overall Study Principal Investigator:

Melinda Merchant, MD, PhD
Staff Clinician, Pediatric Oncology Branch
National Cancer Institute

SARC009
Trial of Dasatinib in Advanced Sarcomas
Type of Sarcoma: Leiomyosarcoma, liposarcoma, MFH/pleomorphic undifferentiated sarcoma, rhabdomyosarcoma, malignant peripheral nerve sheath tumor, osteosarcoma (skeletal or extraosseous), chondrosarcoma, ewing’s, alveolar soft part sarcoma, chordoma, epithelioid sarcoma, giant cell tumor of bone, hemangiopericytoma/solitary fibrous tumor, gastrointestinal stromal tumors (GIST)
Drug: Dasatinib
Accrual Status: Ongoing,Not Accruing
Overall Study Principal Investigator:

Scott Schuetze, MD, PhD
University of Michigan

ESP1 / SARC025 - SPORE03
ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide or Irinotecan in Patients With Previously Treated, Incurable Ewing Sarcoma
Type of Sarcoma: Ewing Sarcoma
Drug: Niraparib and Temozolomide or Irinotecan
Accrual Status: Recruiting
Overall Study Principal Investigator:
Sandra Strauss, MD, PhD
Senior Lecturer and Consultant Medical Oncologist
University College London, Cancer Institute

Rashmi Chugh, MD
Assistant Professor
University of Michigan

Closed SARC Trials

SARC022
Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors
Type of Sarcoma: Gastrointestinal stromal tumors
Drug: OSI-906
Accrual Status: Completed
SARC021
A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma
Type of Sarcoma: Locally advanced or metastatic soft tissue sarcoma
Drug: TH-302 combined with doxorubicin vs. doxorubicin alone
Accrual Status: Completed
SARC020
Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma
Type of Sarcoma: Advanced or Metastatic Untreated Soft Tissue Sarcoma
Drug: Trabectedin Infused to Doxorubicin
Accrual Status: Terminated
SARC019
Study of Dose Escalation Versus no Dose Escalation of Imatinib in Metastatic Gastrointestinal Stromal Tumors (GIST) Patients
Type of Sarcoma: Metastatic GIST
Drug: Imatinib
Accrual Status: Terminated
SARC011
A Study of R1507 in Participants With Recurrent or Refractory Sarcoma
Type of Sarcoma: Ewing’s sarcoma, osteosarcoma, synovial sarcoma, rhabdomyosarcoma, alveolar soft part sarcoma, desmoplastic small round cell tumor, extraskeletal myxoid chondrosarcoma, clear cell sarcoma
Drug: R1507
Accrual Status: Completed
SARC007
A Trial of Perifosine in Patients With Chemo-Insensitive Sarcomas
Type of Sarcoma: Chondrosarcoma, extra-skeletal myxoid chondrosarcoma or alveolar soft part sarcoma
Drug: Perifosine
Accrual Status: Completed
SARC006
Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors
Type of Sarcoma: Malignant peripheral nerve sheath tumors sporadic or NF1 associated
Drug: Adriamycin/ifosfamide and Adriamycin/etoposide
Accrual Status: Completed
SARC005
Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma
Type of Sarcoma: Uterine Leiomyosarcoma
Drug: Gemcitabine and Docetaxel
Accrual Status: Completed
SARC004
Neoadjuvant Imatinib in Dermatofibrosarcoma Protuberans
Type of Sarcoma: Dermatofirbrosarcoma Protuberans
Drug: Gleevec (Imatinib Mesylate)
Accrual Status: Completed
SARC003
Gemcitabine and Docetaxel in Treating Patients With Recurrent Osteosarcoma (Closed to Accrual as of 12/21/06) or Ewing's Sarcoma or Unresectable or Locally Recurrent Chondrosarcoma
Type of Sarcoma: Recurrent Ewing’s Sarcoma, Osteosarcoma, or Unresectable or Locally Recurrent Chondrosarcoma
Drug: Gemcitabine and Docetaxel
Accrual Status: Completed
SARC002
Comparison of Gemcitabine v. Gemcitabine Plus Docetaxel in Unresectable Soft Tissue Sarcoma
Type of Sarcoma: Unresectable soft tissue sarcoma
Drug: Gemcitabine and Docetaxel
Accrual Status: Completed
SARC001
Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma
Type of Sarcoma: Ewing's Family (including PNET), OsteosarcomaSynovial Sarcoma, Leiomyosarcoma, Rhabdomyosarcoma (including alveolar, embryonal and pleomorphic), Liposarcoma (all variants), Malignant Fibrous Histiocytoma, Peripheral Nerve Sheath (including MPNST, neurofibrosarcoma, schwannoma), Fibrosarcoma, Angiosarcoma (all variants), Desmoid Tumor, GI Stromal (c-kit negative only)
Drug: Imatinib Mesylate (Gleevec)
Accrual Status: Completed